Edwards Lifesciences (EW) Operating Leases (2019 - 2026)

Edwards Lifesciences has reported Operating Leases for 8 years, with the latest figure at $81.6 million in Q2 2026.

• On a quarterly basis, Operating Leases rose 3.68% year-over-year to $81.6 million in Q2 2026; TTM through Jun 2026 was $81.6 million, a 3.68% increase from a year earlier, with the FY2025 full-year figure at $82.6 million, down 19.26% from the prior year.
• Operating Leases was $81.6 million for Q2 2026 at Edwards Lifesciences, up from $80.1 million in the prior quarter.
• The five-year high for Operating Leases was $102.3 million in Q4 2024, with the low at $63.5 million in Q2 2022.
• Average Operating Leases over 5 years is $77.6 million, with a median of $77.6 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Operating Leases gained 21.43% in 2024, then declined 19.26% in 2025.
• Over 5 years, Operating Leases stood at $95.0 million in 2022, then retreated by 7.26% to $88.1 million in 2023, then increased by 16.12% to $102.3 million in 2024, then decreased by 19.26% to $82.6 million in 2025, then slipped by 1.21% to $81.6 million in 2026.
• The last three Operating Leases figures came in at $81.6 million (Q2 2026), $80.1 million (Q1 2026), and $82.6 million (Q4 2025), per Business Quant data.